Aavas Financiers Limited (NSE:AAVAS)

Sage Therapeutics Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	5,741	4,907	4,296	3,552	2,889
Depreciation & Amortization	364.52	300.42	260.33	217.92	185.99
Other Amortization	-	26.18	26.87	19.68	20.12
Loss (Gain) From Sale of Investments	-218.56	-165.82	-96.17	-	-
Provision for Credit Losses	-313.43	-280.4	-318.51	-224.06	156.33
Stock-Based Compensation	127.5	86.05	164.17	178.46	85.08
Change in Other Net Operating Assets	-22,626	-24,859	-23,903	-15,367	-14,195
Other Operating Activities	328.86	123.17	328.55	272.51	146.72
Operating Cash Flow	-16,601	-19,866	-19,241	-11,351	-10,712
Capital Expenditures	-300.71	-327.44	-389.52	-155.96	-82.92
Sale of Property, Plant & Equipment	20.11	13.35	5.05	3.56	3.13
Divestitures	0.52	117.63	-	-	-
Investment in Securities	2,042	-6,272	2,341	-4,474	-2,569
Investing Cash Flow	1,762	-6,468	1,957	-4,626	-2,649
Long-Term Debt Issued	45,778	45,097	38,114	36,117	23,518
Long-Term Debt Repaid	-30,966	-20,347	-19,606	-19,960	-13,482
Net Debt Issued (Repaid)	14,812	24,751	18,507	16,156	10,037
Issuance of Common Stock	3.06	22.52	75.38	104.71	46.65
Other Financing Activities	-68.5	-0.5	-	-26.57	-7.35
Financing Cash Flow	14,747	24,773	18,583	16,234	10,076
Net Cash Flow	-92.45	-1,571	1,298	257.13	-3,285
Free Cash Flow	-16,902	-20,193	-19,631	-11,507	-10,795
Free Cash Flow Margin	-127.68%	-172.83%	-194.97%	-142.85%	-176.95%
Free Cash Flow Per Share	-211.88	-254.88	-247.93	-145.19	-136.53
Cash Interest Paid	9,503	7,756	5,481	4,318	3,996
Cash Income Tax Paid	1,321	1,306	929.67	748.18	541.96

Source: S&P Global Market Intelligence. Financial Services template. Financial Sources.